FDA approves Eli Lilly's eczema treatment, Ebglyss, for moderate-to-severe atopic dermatitis in adults/children 12+.

The FDA has approved Eli Lilly's eczema treatment, Ebglyss (lebrikizumab-lbkz), for adults and children aged 12 and older with moderate-to-severe atopic dermatitis. The approval follows three studies with over 1,000 patients who struggled to manage their symptoms with existing treatments. This marks a reversal from last year's rejection due to manufacturing concerns. Ebglyss will be available in the coming weeks.

September 13, 2024
8 Articles

Further Reading